Martin Shkreli, former chief executive officer of Turing Pharmaceuticals, appearing before the House Committee on Oversight and Government Reform during a hearing titled “Developments in the Prescription Drug Market,” on Feb. 4, 2016.
After reviewing motions to dismiss an antitrust lawsuit against pharmaceutical CEO-turned-convicted-felon Martin Shkreli and others, a federal judge in Pennsylvania has ordered additional discovery regarding defense claims that the plaintiff is a “made-for-litigation shell company” formed by a former Winston & Strawn associate.
The lawsuit, brought by Spring Pharmaceuticals, alleges defendants Shkreli, Retrophin, Mission Pharmaceutical Co. and Alamo Pharma Services monopolized the market for a kidney drug by blocking competition from generic drug makers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
